Telbivudine and adefovir combination therapy for patients with chronic lamivudine-resistant hepatitis B virus infections
2014
Lin, Ming-Tsung | Chou, Yeh-Pin | Hu, Tsung-Hui | Yu, Hsien-Chung | Xu, Youjun | Tsai, Ming-Chao | Tseng, Po-Lin | Chang, Kuo-Chin | Yen, Yi-Hao | Chiu, King-Wah
We evaluated second-line salvage therapy with adefovir + telbivudine (group 1), adefovir followed by adefovir + telbivudine (group 2), or lamivudine + adefovir followed by adefovir + telbivudine (group 3) in hepatitis B patients with an inadequate virologic response to lamivudine treatment. Simple linear regression analysis showed that for each additional month of treatment, the most significant reduction in viral load occurred in group 1 (HBV DNA [Log₁₀ IU/mL]: group 1, −0.149; group 2, -0.081; group 3, −0.123). Generalized estimating equation analysis revealed that compared to group 1, hepatitis B virus (HBV) DNA levels were 1.203 and 0.443 Log₁₀ IU/mL higher in groups 2 and 3, respectively. Overall, a significant reduction in viral load (−0.060 Log₁₀ IU/mL) was observed for each additional month of treatment. Adefovir + telbivudine treatment resulted in a significant reduction in HBV DNA levels. Moreover, telbivudine treatment resulted in a significant reduction in viral load (−0.050 Log₁₀ IU/mL) compared to lamivudine treatment after the emergence of lamivudine resistance.
Mostrar más [+] Menos [-]Palabras clave de AGROVOC
Información bibliográfica
Este registro bibliográfico ha sido proporcionado por National Agricultural Library